← Back to Patent Explorer
US4613497A Expired / Lapsed US ⏱️ 0.0 years remaining

Dry, water-foamable pharmaceutical compositions

Assignee: Health Products Development Inc
•
Filing: 1984-02-29
•
Granted: 1986-09-23
•
Expires: 2004-02-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A substantially anhydrous foamable composition capable of forming a substantially stable foam on contact with water is formed from a mixture of water soluble polysaccharide gum, an effervescent base and a biocompatible gelling salt. These compositions upon contact with water form extremely stable foams which are capable of acting as carriers for pharmaceutically active compositions.

Inventors

  • 👤 Leonard Chavkin

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 08:04
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0007; A61K9/0012; A61K9/0034

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 177 words
A substantially anhydrous foamable composition capable of forming a substantially stable foam on contact with water comprising: (a) 20-75 parts by weight of a water soluble polysaccharide gum, (b) 10 to 50 parts by weight of an effervescent base comprising an alkali metal carbonate or bicarbonate and a water soluble biocompatible acid or acid salt and (c) 10% to 100% by weight relative to the weight of gum used, of a soluble biocompatible calcium gelling salt, or potassium gelling salt, to the extent that said proportion of potassium salt is not met by the alkali metal carbonate or bicarbonate of (b) where said alkali metal is potassium wherein; the gum is selected from the group consisting of sodium or potassium alginate, sodium kappa carrageenan or sodium iota carrageenan, the acid component of the effervescent base is fruit acid or a biocompatible acid salt and the gelling salt is selected from the group consisting of calcium gluconate, lactate, citrate, formate, chloride, provided that where the gum is kappa carrageenan then the salt is the corresponding soluble potassium salt.
Claim 2
Dependent Claim 177 words
A substantially anhydrous foamable composition capable of forming a substantially stable foam on contact with water comprising: (a) 20-75 parts by weight of a water soluble polysaccharide gum, (b) 10 to 50 parts by weight of an effervescent base comprising an alkali metal carbonate or bicarbonate and a water soluble biocompatible acid or acid salt and (c) 10% to 100% by weight relative to the weight of gum used, of a soluble biocompatible calcium gelling salt, or potassium gelling salt, to the extent that said proportion of potassium salt is not met by the alkali metal carbonate or bicarbonate of (b) where said alkali metal is potassium wherein; the gum is selected from the group consisting of sodium or potassium alginate, sodium kappa carrageenan or sodium iota carrageenan, the acid component of the effervescent base is fruit acid or a biocompatible acid salt and the gelling salt is selected from the group consisting of calcium gluconate, lactate, citrate, formate, chloride, provided that where the gum is kappa carrageenan then the salt is the corresponding soluble potassium salt.
Claim 3
Dependent Claim 31 words
A sustained release gastric depot composition for the administration of a gastrically administrable pharmaceutically active agent comprising a composition of claim 1 and an effective amount of said pharmaceutically active agent.
Claim 4
Dependent Claim 27 words
A composition according to claim 2 wherein the amount of pharmaceutically active agent is between 1 and 50% by weight of the weight of the foamable composition.
Claim 5
Dependent Claim 16 words
A gastric antiacid composition of claim 2 comprising said foamable composition and a gastric antiacid material.
Claim 6
Dependent Claim 34 words
A composition in accordance with claim 4 wherein the antiacid material comprises at least one member selected from the group consisting of a basic salt of calcium, magnesium, aluminum, bismuth or an hydroxide thereof.
Claim 7
Dependent Claim 20 words
A composition of claim 5 wherein the antiacid material comprises between 10 and 40 wt. percent of the foamable composition.
Claim 8
Dependent Claim 32 words
A composition in accordance with claim 2 wherein the pharmaceutically active agent is selected from the group consisting of a sympathomimetic amine, an antihistamine, an antitussive, an analgesic and a muscle relaxant.
Claim 9
Dependent Claim 33 words
A composition of claim 7 wherein the sympathomimetic amines are selected from the group consisting of phenylpropanolamine, ephedrine, and pseudoephedrine, the antihistamine is chlorpheniramine, the antitussive is dextromethorphan, and the analgesic is acetaminophen.
Claim 10
Dependent Claim 31 words
A sustained release vaginal depot composition for the administration of a vaginally administrable pharmaceutically active agent comprising a composition of claim 1 and an effective amount of said pharmaceutically active agent.
Claim 11
Dependent Claim 27 words
A composition according to claim 9 wherein the amount of pharmaceutically active composition is between 1 and 50% by weight of the weight of the foamable composition.
Claim 12
Dependent Claim 33 words
A contraceptive composition of claim 10 introducable into the female vagina in dry form comprising said foamable composition and between 1 and 50% by weight of said composition of a spermicidally active agent.
Claim 13
Dependent Claim 13 words
A composition of claim 11 wherein the spermicide is nonoxynol, octoxonol, or mefengol.
Claim 14
Dependent Claim 20 words
A composition of claim 12 wherein the spermicidal composition comprises between 2 and 8% by weight of the foamable composition.
Claim 15
Dependent Claim 24 words
A vaginal buffering agent in accordance with claim 9 which comprises said foamable composition and an additional amount of said acid or acid salt.
Claim 16
Dependent Claim 23 words
A composition in accordance with claim 14 wherein the amount of acid is between 10 and 40% by weight of the foamable composition.

References Cited (Backward Citations)

US3947566A Cited
US4309408A Cited
US4187286A Cited
US4322399A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-09-22 1990-03-24 1990-09-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-09-22 1994-03-24 1994-09-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-09-22 1998-03-24 1998-09-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag